Pierre Fabre to commercialize Ebvallo in Europe and MENA region
The European Commission (EC) marketing authorization (MA) that was granted in December to US biotech Atara Biotherapies (Nasdaq: ATRA) for Ebvallo (tabelecleucel) has been transferred to privately French drugmaker Pierre Fabre.
As a result, from today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, the Middle East, Africa and other selected markets. Pierre Fabre is planning to launch Ebvallo in the first European countries during the first quarter of this year.
Under a previously announced license agreement with Atara, Pierre Fabre would lead all commercialization and distribution activities in Europe and select other markets, in addition to medical and regulatory activities following the transfer of the MAA from Atara to Pierre Fabre. Atara became eligible for a $30 million milestone payment from Fabre due to the approval.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze